NEW YORK (GenomeWeb News) – Dako has signed an agreement with Genentech to partner on the regulatory submission of companion diagnostic tests for a breast cancer drug.

Under the agreement announced today, the companies will collaborate on the US Food and Drug Administration submission of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for Genentech's trastuzumab emtansine, an investigational drug candidate for patients with advanced HER2-positive breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.